This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-18. Anything still debated is marked as such rather than presented as settled.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
== Pharmacology == Dimethyl fumarate is metabolized to monomethyl fumarate (MMF) prior to entering systemic distribution. Dimethyl fumarate has been described a prodrug. Dimethyl fumarate is a precursor of monomethyl fumarate. Other prodrugs that metabolize to monomethyl fumarate have been developed to treat relapse-remitting multiple sclerosis, including diroximel fumarate which was approved by the FDA in October 2019. The precise mechanism of action of dimethyl fumarate is not clear. Dimethyl fumarate and monomethyl fumarate can activate the transcription factor (Nuclear factor erythroid-derived 2)-related factor 2 (Nrf2) pathway and monomethyl fumarate has been identified as a nicotinic acid receptor agonist in vitro. In mice that lack Nrf2 expression, however, dimethyl fumarate is still able to modulate the immune system, which indicates that Nrf2 is not required for its immunomodulatory action. For psoriasis, the mechanism of action is believed to be due to the interaction of monomethyl fumarate and the intracellular reduced glutathione of cells directly involved in the pathogenesis of psoriasis. The interaction with glutathione leads to the inhibition of nuclear translocation and the transcriptional activity of the nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB). Dimethyl fumarate and monomethyl fumarate have been shown to reduce the expression of micro-RNA-21, which is essential for the production of pathogenic cells in multiple sclerosis and psoriasis.
== Taste and texture == Cheaper cuts of meat with connective tissue and lean muscle fibers are suitable for stewing, as long slow cooking softens connective tissue without toughening the muscle. Slow cooking leaves gelatinized tissue in the meat, so that it may be advantageous to start with a richer liquid. The low temperature of slow-cooking makes it almost impossible to burn even food that has been cooked too long. However, some meats and most vegetables become nearly tasteless or "raggy" if over-cooked. Slow cookers do not provide sufficient heat to compensate for loss of moisture and heat due to frequent removal of the lid, e.g., to add and remove food in perpetual stews, (pot-au-feu, olla podrida). Added ingredients must be given time to cook before the food can be eaten.
Barbell Bowflex Bulgarian bag Cable machine Captains of Crush Grippers Dip bar Dumbbell Halteres (ancient Greece) Indian clubs Iron rings IronMind Kettlebell Leg press Power cage Shake Weight Smith machine Soloflex Swimming machine Total Gym Trap bar TRX System Universal Gym Equipment Utility bench Weight machine York Barbell
Sources: en.wikipedia.org
Prednisone is a synthetic glucocorticoid used for its anti-inflammatory and immunosuppressive properties. Prednisone is a prodrug; it is metabolised in the liver by 11-β-HSD to prednisolone, the active drug. Prednisone has no substantial biological effects until converted via hepatic metabolism to prednisolone.
Other large parks are Parco della Pellerina, Parco Colletta, Parco Rignon, Parco Colonnetti and the University botanical gardens. Around the city are several other parks such as La Mandria Regional Park and the Parco della Palazzina di Caccia di Stupinigi, once hunting grounds of the Savoy, and those on the hills of Turin. Many parks are smaller, in the various districts: there is also a total of 240 playgrounds in these parks. In the early 1960s, mayor Amedeo Peyron had the first garden in Italy with games for children inaugurated. According to a Legambiente report from 2007, Turin is the first Italian city as far as structures and policies on childcare are concerned. One of the most famous parks featuring a children's playground is Parco della Tesoriera, which is also home to Andrea della Corte Municipal Music Library; this facility is housed in Villa Tesoriera, built in 1715 and once the Royal Treasurer's residence. The park is in the Parella suburb (Turin's West Side) and hosts many concerts in summer. Rosa Vercellana, commonly known as Rosina and, in Piedmontese as La Bela Rosin ('The Beautiful Rosin'), was the mistress and later wife of King Victor Emmanuel II. She was made Countess of Mirafiori and Fontanafredda, but never Queen of Italy. As the Savoy family refused to allow her to be buried next to her husband in the Pantheon, her children had a mausoleum built for her in a similar form and on a smaller scale in Turin, next to the road to the Castello di Mirafiori.
== Potential drug targets == In the treatment of epilepsy, drugs such as vigabatrin that target both GABA transporters and the GABA metabolizing enzyme GABA-transaminase have been marketed, providing proof of principle for the neurotransmitter cycling systems as pharmacological targets. However, with regard to glutamate transport and metabolism, no such drugs have been developed, because glutamatergic synapses are abundant, and the neurotransmitter glutamate is an important metabolite in metabolism, making interference capable of adverse effects. So far, most of the drug development directed at the glutamatergic system seems to have been focused on ionotropic glutamate receptors as pharmacological targets, although G-protein coupled receptors have been attracting increased attention over the years.
its speed. On this basis, du Châtelet proposed that energy must always have the same dimensions in any form, which is necessary to be able to consider it in different forms (kinetic, potential, heat, ...). Engineers such as John Smeaton, Peter Ewart, Carl Holtzmann, Gustave-Adolphe Hirn, and Marc Seguin recognized that conservation of momentum alone was not adequate for practical calculation and made use of Leibniz's principle. The principle was also championed by some chemists such as William Hyde Wollaston. Academics such as John Playfair were quick to point out that kinetic energy is clearly not conserved. This is obvious to a modern analysis based on the second law of thermodynamics, but in the 18th and 19th centuries, the fate of the lost energy was still unknown. Gradually it came to be suspected that the heat inevitably generated by motion under friction was another form of vis viva. In 1783, Antoine Lavoisier and Pierre-Simon Laplace reviewed the two competing theories of vis viva and caloric theory. Count Rumford's 1798 observations of heat generation during the boring of cannons added more weight to the view that mechanical motion could be converted into heat and (that it was important) that the conversion was quantitative and could be predicted (allowing for a universal conversion constant between kinetic energy and heat). Vis viva then started to be known as energy, after the term was first used in that sense by Thomas Young in 1807.
Sources: en.wikipedia.org
==== Anima and animus ==== Jung argued that the unconscious of every man contains a complementary feminine element (the anima) and every woman a complementary masculine element (the animus). Within these complementary elements exist an inherited collective image of 'man' and 'woman' respectively, which only becomes conscious in actual contacts with men and women. As such, these are archetypes of the collective unconscious. These counterparts come in part from this inherited collective image, but also partly through a person's contact with the opposite gender in their life (particularly their parental figures), and partly through the latent masculinity (for women) and femininity (for men) that a person experiences in themselves. Like the shadow, if a person rejects their anima or animus, it is more likely to be projected outwards.
=== Hurdles === Given the uneven distribution of vaccines across jurisdictions, granting privileges based on vaccination status certification means that those with easier vaccine access have unfair access to those privileges. If vaccination status is only verifiable using digital technology, those without that technology may also lose access even if they are vaccinated. Such privileging mechanisms may exacerbate inequality, increase risks of deliberate infections or transmission, Public health justifications for restricting behavior based on vaccine status have become less frequent over the course of the pandemic as vaccines do not stop transmission.
Poole integrates into the society of 3001, but is prompted by a friend to revisit Europa, a cradle of nascent life from which the monolith had banned humanity almost a millennium earlier. It is believed he might be the first person allowed to visit there. On Europa he is greeted by the voice of David Bowman and computer HAL 9000, who have now become a single entity—Halman—residing as digitized lifeforms in the monolith's computational matrix. In subsequent conversations he learns that the monoliths themselves are mechanisms, answerable to an unknown superior monolith, or perhaps lifeforms, almost 450 light-years away. Thirty years later, Poole is married, and a member of a small team responsible for monitoring Europa. Halman contacts him to warn that following the events of 2010: Odyssey Two and 2061: Odyssey Three, the Jovian monolith had sent a report to its superior monolith, containing details about the human species after first contact. Since this report took place shortly after the wars of the 20th century, Halman believes the response just received after the 900-year round trip contains instructions to destroy humanity, due to its perceived failure as a species. Unsure whether they can physically harm the Monolith, the Europa team decide instead to infect it—as a computational mechanism—with a computer virus. Poole requests Halman to act as a Trojan Horse and place the virus inside the monolith, where it will be executed.
=== Malignancy (Type V) === Malignant acanthosis nigricans is a paraneoplastic syndrome most often associated with gastrointestinal adenocarcinomas, particularly gastric cancer. Less commonly, it occurs with malignancies of the breast, ovary, prostate, thyroid, lung or lymphoid tissues. It may precede, accompany or follow a cancer diagnosis. Mucosal involvement is more common than in benign forms. Additional findings may include multiple seborrhoeic keratoses, skin tags and tripe palms.
Vasopressin is released into the brain in a circadian rhythm by neurons of the suprachiasmatic nucleus. Vasopressin released from posterior pituitary is associated with nausea. Recent evidence suggests that vasopressin may have analgesic effects. The analgesia effects of vasopressin were found to be dependent on both stress and sex.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.